These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23060539)

  • 1. New perspectives in the treatment of neuroendocrine tumours.
    Bajetta E; Catena L; Valente M; Bianco N; Bellomo F; Bombardieri E
    Anticancer Res; 2012 Oct; 32(10):4193-200. PubMed ID: 23060539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
    Hodolic M; Fettich J; Marzola MC; Tonini E; Al-Nahhas A; Rubello D
    In Vivo; 2010; 24(1):97-100. PubMed ID: 20133983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
    Basu B; Sirohi B; Corrie P
    Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [State of the art and therapeutic prospects in neuroectodermal tumours and other neuroendocrine pathologies].
    Guida T; Belsito Petrizzi V; Fiorentino R; Germano D; Guardasi R; Lentini-Graziano ML; Cartenì G
    Minerva Endocrinol; 2001 Dec; 26(4):215-24. PubMed ID: 11782706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
    Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
    Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the treatment of neuroendocrine tumors.
    Bajetta E; Procopio G; Ferrari L; Catena L; Del Vecchio M; Bombardieri E
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):631-42. PubMed ID: 14599087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analogs for the treatment of neuroendocrine tumors.
    Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of neuroendocrine tumours of the gastrointestinal tract].
    Hansen CP; Langer S; Frevert S; Mortensen J; Kjaer A; Knigge U
    Ugeskr Laeger; 2010 Oct; 172(43):2942-5. PubMed ID: 21040671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
    Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
    Grozinsky-Glasberg S; Grossman AB; Korbonits M
    Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours].
    Colao A; Pulcrano M; Dorato M; Müller F; Rossi FW; De Martino MC; Biondi B; Lombardi G
    Minerva Endocrinol; 2001 Dec; 26(4):231-8. PubMed ID: 11782708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.